Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Deficiency of parkin causes neurodegeneration and accumulation of pathological α-synuclein in monkey models
Rui Han, … , Xiao-Jiang Li, Weili Yang
Rui Han, … , Xiao-Jiang Li, Weili Yang
Published October 15, 2024
Citation Information: J Clin Invest. 2024;134(20):e179633. https://doi.org/10.1172/JCI179633.
View: Text | PDF
Research Article Aging Neuroscience

Deficiency of parkin causes neurodegeneration and accumulation of pathological α-synuclein in monkey models

  • Text
  • PDF
Abstract

Parkinson’s disease (PD) is characterized by age-dependent neurodegeneration and the accumulation of toxic phosphorylated α-synuclein (pS129-α-syn). The mechanisms underlying these crucial pathological changes remain unclear. Mutations in parkin RBR E3 ubiquitin protein ligase (PARK2), the gene encoding parkin that is phosphorylated by PTEN-induced putative kinase 1 (PINK1) to participate in mitophagy, cause early onset PD. However, current parkin-KO mouse and pig models do not exhibit neurodegeneration. In the current study, we utilized CRISPR/Cas9 technology to establish parkin-deficient monkey models at different ages. We found that parkin deficiency leads to substantia nigra neurodegeneration in adult monkey brains and that parkin phosphorylation decreases with aging, primarily due to increased insolubility of parkin. Phosphorylated parkin is important for neuroprotection and the reduction of pS129-α-syn. Consistently, overexpression of WT parkin, but not a mutant form that cannot be phosphorylated by PINK1, reduced the accumulation of pS129-α-syn. These findings identify parkin phosphorylation as a key factor in PD pathogenesis and suggest it as a promising target for therapeutic interventions.

Authors

Rui Han, Qi Wang, Xin Xiong, Xiusheng Chen, Zhuchi Tu, Bang Li, Fei Zhang, Chunyu Chen, Mingtian Pan, Ting Xu, Laiqiang Chen, Zhifu Wang, Yanting Liu, Dajian He, Xiangyu Guo, Feng He, Peng Wu, Peng Yin, Yunbo Liu, Xiaoxin Yan, Shihua Li, Xiao-Jiang Li, Weili Yang

×

Figure 2

Targeting parkin in the adult monkey brain leads to SN neurodegeneration.

Options: View larger image (or click on image) Download as PowerPoint
Targeting parkin in the adult monkey brain leads to SN neurodegeneration...
(A) The monkey parkin gene (PARK2) was targeted by stereotaxic injection of AAV9-parkin gRNA-RFP/Cas9 into the monkey brain region. A control group was injected with AAV-Cas9 along with control gRNA-RFP. (B) Low-magnification micrographs show viral infection reflected by RFP in the injected monkey SN. Scale bar: 1.5 mm. (C) Double immunofluorescent staining indicates that AAV9-parkin gRNA-RFP/Cas9-infected neurons (arrows) in the SN displayed reduced expression of parkin. (D and E) Representative images of immunofluorescent staining revealed that targeting parkin in the SN of 6- or 25-year-old monkeys (E) resulted in a reduction of TH-positive neurons as compared with AAV-control gRNA-injected SN (D). Enlarged images in white boxed areas in the control gRNA groups are also presented to show viral infection of neuronal cells. Scale bar: 5 μm. Representative immunofluorescent staining images in B–E are from at least 3 biological replicates with multiple technical replicates. (F) Superplot analysis of the number of TH-positive neurons in the SN of monkeys injected with AAV-Cas9/control-gRNA and AAV-Cas9/parkin-gRNA. The experimental groups included 4 young monkeys aged 6–8 years and 3 old monkeys aged 25–28 years. The number of TH-positive cells in each image (×20) was recorded and color coded to represent the specific monkey brain it originated from. The average count of TH-positive cells in each animal was used for paired 2-tailed t test to obtain the P values. Data are represented as means ± SEM (n = 4 for 6-8 years and n = 3 for 25–28 years).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts